For patients with CKD without T2DM, the recommendation is to initiate treatment with SGLT2 inhibitors in addition to maximum tolerated renin-angiotensin-aldosterone system (RAAS) blockade in patients with very high KDIGO risk and an eGFR >20ml/min/1.73m2 [15]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.